Yutrepia (treprostinil inhalation powder)
An approved treatment for Pulmonary Arterial Hypertension.
The same compound appears under different names depending on the context. Here is how to identify Treprostinil inhalation powder wherever you encounter it, plus the key facts at a glance.
- Generic name
- Treprostinil inhalation powder
- Brand name
- Yutrepia
- Development code
- LIQ861
- Drug class
- Prostacyclin analog (inhaled dry powder)
- Manufacturer
- Liquidia Corporation
- How it's taken
- Taken by oral inhalation using a small, breath-actuated dry-powder inhaler.
An inhaled dry-powder formulation of treprostinil for adults with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Made with Liquidia's PRINT particle-engineering technology and delivered through a small, low-effort handheld inhaler.
We'll email you when Yutrepia's FDA label changes, when the FDA acts on it, and when new trials for Pulmonary Arterial Hypertension open. Unsubscribe anytime.
Where Treprostinil inhalation powder fits
Distinct from Tyvaso DPI (United Therapeutics), both are dry-powder inhaled treprostinil, but Yutrepia uses Liquidia's PRINT-engineered particles and a different inhaler. Indicated for both PAH and PH-ILD, giving patients a third inhaled treprostinil option (alongside Tyvaso nebulizer and Tyvaso DPI).
How Treprostinil inhalation powder works
Yutrepia is the same active drug as Tyvaso (treprostinil) but engineered as uniform dry-powder particles using Liquidia's PRINT technology. The particles are designed to reach deep into the lungs with less inspiratory effort than older dry-powder devices. Once absorbed, treprostinil mimics prostacyclin, relaxing narrowed pulmonary blood vessels, reducing platelet clumping, and improving blood flow through the lungs.
Mechanism: Prostacyclin analog delivered as a dry-powder inhalation, dilates pulmonary arteries and inhibits platelet aggregation
Side effects and safety
Most common side effects are cough, headache, throat irritation, nausea, flushing, and dizziness. Like other inhaled prostacyclins, jaw pain can occur. Bronchospasm is possible, particularly in patients with reactive airway disease. The label also warns about low blood pressure, a higher risk of bleeding (treprostinil slows platelet clumping), and dose changes when drugs that affect the liver enzyme CYP2C8 are started or stopped.
This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.
Taking Treprostinil inhalation powder
Taken by oral inhalation using a small, breath-actuated dry-powder inhaler. Dosing is titrated up over time as tolerated, typically given multiple times per day. No nebulizer, batteries, or refrigerated cassettes required, which is the key practical differentiator from Tyvaso nebulizer and Tyvaso DPI.
Availability and cost
Only available as the brand-name product.
Branded inhaled treprostinil delivered via a proprietary dry-powder device. Pricing reflects PRINT-based particle engineering and the device platform, similar to other branded inhaled prostacyclin formulations.
Help paying for Yutrepia
Pick your insurance to see which help fits. Drugmaker copay cards can't be used with Medicare, Medicaid or TRICARE; charity funds are the usual route there.
- Copay help
The YUTREPIA Co-Pay Program gives financial help to eligible commercially insured patients.
For: private insurance · source - Free medicine program
The YUTREPIA Patient Assistance Program may give medicine at no cost to eligible patients who cannot afford their out-of-pocket costs.
The official page does not say who qualifies. Ask the program. · source - Bridge or quick-start supply
Bridge Program: one-time 28-day supply for eligible patients who cannot get their prescribed medicine right away.
The official page does not say who qualifies. Ask the program. · source - Other support
Voucher Program: one-time free 28-day supply for new patients to see if YUTREPIA is right for them.
The official page does not say who qualifies. Ask the program. · source - Insurance and case manager help
Specialty pharmacies help with insurance and financial assistance, deliver the medicine, and provide in-home training.
The official page does not say who qualifies. Ask the program. · source
Good to know: Official pages do not say how much the copay program covers, or the income or insurance rules for the Patient Assistance Program. Programs are handled through the specialty pharmacy.
- From a charity · HealthWell FoundationPulmonary Hypertension (Medicare Access) fundOpen
Pays for: Copays, premiums or other treatment costs. Medicare patients only.
- From a charity · TotalAssist (formerly PAN Foundation)Pulmonary Hypertension fundOpen
Pays for: Out-of-pocket costs for approved medications, up to $9,500 per year. Requires health insurance (any kind).
- From a charity · The Assistance FundPulmonary Hypertension fundWaitlist
Pays for: Copays, coinsurance, deductibles and other health-related expenses.
The foundation says: “WAITLIST — Accepting Waitlist Patients. TAF is currently accepting requests to join the enrollment waitlist for this program. Waitlists a…”
Clinical trial results
FDA approval (May 23, 2025) was supported by the open-label INSPIRE study in 121 adults with PAH, which evaluated long-term safety and tolerability of inhaled treprostinil dry powder, including in patients transitioning from nebulized treprostinil. Pharmacokinetic bridging to the established treprostinil safety and efficacy database supported approval in both PAH and PH-ILD.
Development history
Developed by Liquidia Corporation using its proprietary PRINT particle-engineering platform. After several years of regulatory delays tied to a patent dispute with United Therapeutics over Tyvaso DPI, Yutrepia received final FDA approval on May 23, 2025 for both PAH and PH-ILD.
Explore Pulmonary Arterial Hypertension trials
Other Pulmonary Arterial Hypertension treatments
Common questions about Treprostinil inhalation powder
▸What is Treprostinil inhalation powder (Yutrepia)?
An inhaled dry-powder formulation of treprostinil for adults with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Made with Liquidia's PRINT particle-engineering technology and delivered through a small, low-effort handheld inhaler.
▸How does Treprostinil inhalation powder work?
Yutrepia is the same active drug as Tyvaso (treprostinil) but engineered as uniform dry-powder particles using Liquidia's PRINT technology. The particles are designed to reach deep into the lungs with less inspiratory effort than older dry-powder devices. Once absorbed, treprostinil mimics prostacyclin, relaxing narrowed pulmonary blood vessels, reducing platelet clumping, and improving blood flow through the lungs.
▸What are the side effects of Treprostinil inhalation powder?
Most common side effects are cough, headache, throat irritation, nausea, flushing, and dizziness. Like other inhaled prostacyclins, jaw pain can occur. Bronchospasm is possible, particularly in patients with reactive airway disease. The label also warns about low blood pressure, a higher risk of bleeding (treprostinil slows platelet clumping), and dose changes when drugs that affect the liver enzyme CYP2C8 are started or stopped.
▸How is Treprostinil inhalation powder taken?
Taken by oral inhalation using a small, breath-actuated dry-powder inhaler. Dosing is titrated up over time as tolerated, typically given multiple times per day. No nebulizer, batteries, or refrigerated cassettes required, which is the key practical differentiator from Tyvaso nebulizer and Tyvaso DPI.
▸Is Treprostinil inhalation powder FDA approved?
Yes, Treprostinil inhalation powder (Yutrepia) is FDA approved (2025) for the treatment of Pulmonary Arterial Hypertension.
▸How is Yutrepia different from Tyvaso DPI?
Both are dry-powder inhaled treprostinil products, but they use different particle-engineering technologies and inhaler devices. Yutrepia uses Liquidia's PRINT technology to create uniform particles designed for deep lung deposition with low inspiratory effort. Tyvaso DPI is United Therapeutics' product using their own dry-powder formulation. Both deliver the same active drug (treprostinil) to the lungs. The devices differ in design, and patient preference may vary.
▸Is Yutrepia approved for both PAH and PH-ILD?
Yes. Yutrepia received FDA approval in May 2025 for both pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). This dual indication mirrors the approvals for other treprostinil inhalation products. The approval was supported by the INSPIRE study and pharmacokinetic bridging to the established treprostinil efficacy database.
▸Why was Yutrepia delayed for so long?
Yutrepia's approval was delayed by several years due to a patent dispute with United Therapeutics, which markets the competing Tyvaso products. The legal battle over treprostinil inhalation patents created regulatory uncertainty. After resolution of these patent issues, Liquidia received final FDA approval in May 2025.
▸Does Yutrepia require a nebulizer?
No. Yutrepia is a dry-powder inhaler that does not need a nebulizer, batteries, liquid cassettes, or refrigerated storage. Patients inhale the medication through a small, breath-actuated device. This is a key practical advantage over nebulized treprostinil formulations.